Condition: Graft-Versus-Host Disease · GVHD · Undefined · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD.
This description comes directly from the study's public registry record.
Alina Markova, MD · 6466082342 · markovaa@mskcc.org
Doris Ponce, MD · 646-608-3739 · ponced@mskcc.org
Always discuss trial participation with your own doctor first.
| National Institute of Health (Data Collection AND Specimen Analysis) | Bethesda, Maryland, United States | Recruiting |
| Memorial Sloan Kettering at Basking Ridge (Consent only) | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (Consent only) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center @ Bergen (Consent only) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center @ Commack (Consent only) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (Consent only) | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center @ Nassau (Consent only) | Uniondale, New York, United States | Recruiting |
| University of Pittsburgh Medical Center (Data Collection Only) | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05675930